https://www.bioworld.com/rss en-us Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization. http://www.bioworld.com/articles/732692 Thu, 16 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732692-capital-remains-selective-in-barbell-biotech-market International currency symbols Fosun Pharma subsidiary Fosun Pharmaceutical Industrial Development (Shenzhen) Co. Ltd. has received approval from China’s National Medical Products Administration (NMPA) to commence clinical trials for FXR-0906 for the treatment of hypertriglyceridemia. http://www.bioworld.com/articles/732676 Thu, 16 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732676-fosun-cleared-to-conduct-clinical-trials-with-fxr-0906 Illustration of lipids in the bloodstream Hansoh Pharmaceutical Group Co. Ltd. has taken a new step in the evolution of China’s “newco” strategy, combining its newly created U.S. company, Avere Therapeutics Inc., with Nasdaq-listed Nextcure Inc. in a deal designed less to merge pipelines than to create a public vehicle for global development of a China-originated asset. http://www.bioworld.com/articles/732610 Wed, 15 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732610-hansoh-takes-newco-route-to-globalize-il-23-asset Glass globe with documents and pen Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China. http://www.bioworld.com/articles/732667 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732667-chinas-mindrank-raises-52m-series-b-to-advance-oral-glp-1 Blue digital dollar sign The U.S. FDA declined to approve, for a third time, an investigational liver cancer drug regimen comprising HLB Co. Ltd.’s rivoceranib and Jiangsu Hengrui Pharmaceutical Co. Ltd.’s camrelizumab, reportedly citing issues from a drug manufacturing facility inspection. http://www.bioworld.com/articles/732666 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732666-hlb-hengrui-receive-third-us-fda-rejection-on-liver-cancer-combo Liver tumor treatment conceptual illustration Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. http://www.bioworld.com/articles/732665 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732665-astrazeneca-nabs-pde3-4-inhibitor-for-copd-in-21b-sino-deal Red lungs on blue background Drug Farm Biotechnology Co. Ltd. closed a $55 million series D round to advance its AI-developed alpha-protein kinase 1 (ALPK1) inhibitor, DF-003, in a phase III trial for ROSAH syndrome, a rare genetic disease that can lead to blindness. http://www.bioworld.com/articles/732600 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732600-drug-farm-bags-55m-series-d-to-advance-ai-developed-alpk1-drug Blue dollar sign on white background Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd. and its EGFR inhibitor for lung cancer, as well as Innovent Biologics Inc. and its anti-CD40L antibody for a chronic fibroinflammatory condition. http://www.bioworld.com/articles/732598 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732598-asia-deal-flurry-draws-az-spero-to-1b-dizal-innovent-assets Global deals illustration Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China. http://www.bioworld.com/articles/732583 Mon, 13 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732583-chinas-mindrank-raises-52m-series-b-to-advance-oral-glp-1 Blue digital dollar sign The U.S. FDA declined to approve, for a third time, an investigational liver cancer drug regimen comprising HLB Co. Ltd.’s rivoceranib and Jiangsu Hengrui Pharmaceutical Co. Ltd.’s camrelizumab, reportedly citing issues from a drug manufacturing facility inspection. http://www.bioworld.com/articles/732532 Fri, 10 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732532-hlb-hengrui-receive-third-us-fda-rejection-on-liver-cancer-combo Liver tumor treatment conceptual illustration Arnatar Therapeutics Inc. has received clinical trial clearance from China’s National Medical Products Administration (NMPA) for ART-5. http://www.bioworld.com/articles/732482 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732482-art-5-cleared-for-clinic-in-china-for-polycystic-kidney-disease Illustration of polycystic kidney The House Select Committee on China launched an investigation into clinical trials involving U.S. companies that are conducted at Chinese military hospitals and in Xinjiang, China. http://www.bioworld.com/articles/732477 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732477-some-clinical-trials-in-china-under-us-congressional-scrutiny China and U.S. flags Despite the Biosecure Act’s five-year wind-down period that isn’t expected to start until mid-2028, Wuxi Apptec is already feeling the repercussions of being added last month to the U.S. Department of War’s Section 1260H list. http://www.bioworld.com/articles/732475 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732475-wuxi-apptec-seeks-immediate-relief-from-us-listing Legal scales and clipboard Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732472 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732472-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.” BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.”]]> http://www.bioworld.com/articles/732471 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732471-behind-chinas-retractions-a-paper-mill-economy-built-on-incentives China in red on globe As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732470 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732470-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork Astrazeneca plc has returned to China’s CSPC Pharmaceutical Group Ltd. for another discovery collaboration, this time in a deal worth up to $1.77 billion to use CSPC’s siRNA drug discovery platform and extrahepatic targeted delivery technology to develop small nucleic acid drug candidates. http://www.bioworld.com/articles/732469 Tue, 07 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732469-astrazeneca-returns-to-tap-chinas-cspc-in-17b-discovery-deal Deal illustration Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732473 Tue, 07 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732473-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Astrazeneca plc has returned to China’s CSPC Pharmaceutical Group Ltd. for another discovery collaboration, this time in a deal worth up to $1.77 billion to use CSPC’s siRNA drug discovery platform and extrahepatic targeted delivery technology to develop small nucleic acid drug candidates. http://www.bioworld.com/articles/732396 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732396-astrazeneca-returns-to-tap-chinas-cspc-in-17b-discovery-deal Deal illustration Despite the Biosecure Act’s five-year wind-down period that isn’t expected to start until mid-2028, Wuxi Apptec is already feeling the repercussions of being added last month to the U.S. Department of War’s Section 1260H list. Instead of just waiting for its June 11 challenge to its listing as a “Chinese military company” to play out in court, the Shanghai-based contract research, development and manufacturing organization (CRDMO) is now seeking a preliminary injunction to suspend the designation during the court proceedings. http://www.bioworld.com/articles/732276 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732276-wuxi-apptec-seeks-immediate-relief-from-us-listing Legal scales and clipboard Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732271 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732271-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732394 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732394-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork The House Select Committee on China launched an investigation into clinical trials involving U.S. companies that are conducted at Chinese military hospitals and in Xinjiang, China. http://www.bioworld.com/articles/732259 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732259-some-clinical-trials-in-china-under-us-congressional-scrutiny China and U.S. flags As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732258 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732258-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732393 Wed, 01 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732393-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Nature Medicine has retracted a widely publicized Chinese lung cancer study that suggested administering immunotherapy before 3 p.m. could dramatically improve survival in a decision that comes amid heightened scrutiny of research integrity and data transparency in high-impact biomedical journals. Nature Medicine has retracted a widely publicized Chinese lung cancer study that suggested administering immunotherapy before 3 p.m. could dramatically improve survival in a decision that comes amid heightened scrutiny of research integrity and data transparency in high-impact biomedical journals.]]> http://www.bioworld.com/articles/732353 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732353-high-profile-retraction-tests-confidence-in-china-led-studies Retraction spelled out on typewriter The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors. http://www.bioworld.com/articles/732350 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732350-ollins-330m-series-b-underscores-rise-of-china-origin-newco-model Close-up of a human eye featuring a dollar sign in the iris Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results. http://www.bioworld.com/articles/732349 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732349-corxel-vincentages-oral-glp-1-meets-phase-ii-obesity-endpoints Glass of water and tablets Nuvectis Pharma Inc.’s shares climbed further after the oncology-focused biotech nabbed select rights to a late-stage complement factor B inhibitor (HSK-39297/NXP-100) and a phase I BRAF inhibitor (HSK-42360/NXP-200) from Haisco Pharmaceutical Group Co. Ltd. for $40 million up front. http://www.bioworld.com/articles/732348 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732348-nuvectis-shares-continue-to-rally-after-146b-haisco-deal Dollar symbol with arrow graph Abbisko Therapeutics Co. Ltd. has entered a research collaboration and license agreement with Eli Lilly and Co. to discover and develop innovative medicines across multiple targets, with the aim of advancing novel drug candidates with global potential. http://www.bioworld.com/articles/732347 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732347-lilly-taps-abbisko-for-19b-discovery-deal Microscope